RxDoctor Payments Data

Monika Budhathoki

Family · Fort Worth, TXNPI 1588038889

Payments from drug & device makers

$4,284in general payments, 2019–2025

Across 257 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$877
  • Regeneron Healthcare Solutions, Inc.$398
  • Johnson & Johnson$347
  • Takeda Pharmaceuticals U.S.A., Inc.$317
  • QOL Medical, LLC$171
  • plus $804 from 20 others

What the payments were for

  • Food & beverage$4,16197%
  • Education$1223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,284 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$74,054
Medicare patients
518
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide77$82,548
TrulancePlecanatide37$25,974
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg246$5,305
MovantikNaloxegol Oxalate11$5,160
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag34$4,126
Famotidine295$3,549
Omeprazole199$2,711
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C18$2,613
Pantoprazole Sodium202$1,791
Sucralfate33$1,348
Colestipol Hcl19$1,248
Dicyclomine Hcl55$551
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg20$314
Hydrocortisone16$255
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl17$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,370$82,54877 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$877$28,58755 claims
Braintree Laboratories, Inc.Suflave$36$4,12634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →